Randomized, Double-blind, Four Period, Six-treatment, Double-dummy, Placebo Controlled, Partial-crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH) of Cebranopadol, Oxycodone, and Placebo in Healthy Subjects
Latest Information Update: 22 Oct 2024
At a glance
- Drugs Cebranopadol (Primary) ; Oxycodone (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Tris Pharma
Most Recent Events
- 06 Aug 2024 Results published in the Tris Pharma Media Release
- 06 Aug 2024 According to Tris Pharma media release, findings from this trial will be highlighted in a poster session on August 7, 2024, at the International Association for the Study of Pain (IASP) 2024
- 08 May 2024 Status changed from recruiting to completed.